Pencil Biosciences Limited

Pencil is delighted to be included in the Top 10 UK venture seed deals in the Biotech Financing Report 2023, published by the BioIndustry Association (BIA) - https://lnkd.in/e94GgQWd

Pencil is excited that Vertex Pharmaceuticals have secured approval from the MHRA for the worlds first gene editing therapy, for patients with Sickle Cell or Beta Thalassaemia. This therapy utilises CRISPR gene editing technology. https://lnkd.in/ezKhAzkq

Pencil is very pleased to be included in the list of 31 most interesting UK startups. Pencil is growing - see Pencil job postings here: https://lnkd.in/eRWgXVAb

https://lnkd.in/eF5rQBft

⭐ Pencil Biosciences Limited has raised £5.6 million in seed funding ⭐ Based in Chesire, the Pencil team is developing a novel gene modulation technology with the aim of transforming the gene editing landscape. Pencil's technology will be utilised across various applications including new therapeutic options for patients with cancer, genetic and rare diseases. We're really excited to be backing the team as they deliver the next-generation technology for gene editing! Find out more here: https://bit.ly/3LH5opn

We have invested in Pencil Biosciences Limited, the developer of a novel gene modulation technology based on a next generation platform which aims to transform the gene editing landscape as applied to therapeutics and industrial biotechnology, as part of a £5.6 million Seed round. Pencil Biosciences is developing a fully synthetic gene modulation and editing platform that will have impact across a wide range of applications, including new therapeutic options for patients with rare diseases and cancer.   Led by CEO Dr Amanda Smith, primary Founder and CTO Dr Rajik Ibrahim and Chair Dr Jon Moore, Pencil Biosciences will be deepening and widening the capabilities of its proprietary editing and modulation technology, which is modular in design, non-CRISPR in composition and significantly smaller than any Cas-based gene editing technologies.   We look forward to working with the Pencil Biosciences team as they progress with the development of their innovative technology platform which has the potential to transform treatment provided to patients with rare diseases   Read more about our latest investment here: https://bit.ly/3rupegQ

We are excited to share that Pencil BIosciences has raised £ 5.6 million seed funding...